Baseline demographics and disease characteristics
| Characteristic . | Patients (N = 30) . |
|---|---|
| Age, median (range), y | 36 (19-83) |
| Female, n (%) | 17 (56.7) |
| Disease stage at initial diagnosis,∗,† n (%) | |
| I–II | 16 (53.3) |
| III–IV | 13 (43.3) |
| Disease status at enrollment,† n (%) | |
| Relapsed | 7 (23.3) |
| Refractory | 18 (60.0) |
| Relapsed and refractory‡ | 5 (16.7) |
| Previous lines of systemic therapy, median (range)1§ | 2 (2-5) |
| First-line therapy,§ n (%) | |
| R-CHOP | 8 (26.7) |
| R-EPOCH | 9 (30.0) |
| Other‖ | 13 (43.3) |
| Previous rituximab,† n (%) | 30 (100.0) |
| Previous auto-HCT,† n (%) | 4 (13.3) |
| Characteristic . | Patients (N = 30) . |
|---|---|
| Age, median (range), y | 36 (19-83) |
| Female, n (%) | 17 (56.7) |
| Disease stage at initial diagnosis,∗,† n (%) | |
| I–II | 16 (53.3) |
| III–IV | 13 (43.3) |
| Disease status at enrollment,† n (%) | |
| Relapsed | 7 (23.3) |
| Refractory | 18 (60.0) |
| Relapsed and refractory‡ | 5 (16.7) |
| Previous lines of systemic therapy, median (range)1§ | 2 (2-5) |
| First-line therapy,§ n (%) | |
| R-CHOP | 8 (26.7) |
| R-EPOCH | 9 (30.0) |
| Other‖ | 13 (43.3) |
| Previous rituximab,† n (%) | 30 (100.0) |
| Previous auto-HCT,† n (%) | 4 (13.3) |
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-EPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin.
Disease stage at initial diagnosis not reported for 1 patient.
Data from December 2020 database lock, presented at ICML 2021.25
Defined as patients who relapsed after at least 1 prior line of therapy and had no response to the most recent prior therapy.
These data are from the January 2019 database lock.
Other anthracycline-containing therapies.